(Reuters)—The U.S. Attorney’s Office for the Southern District of New York is investigating contracts between drugmakers and companies that manage prescription benefits, according to regulatory filings. Federal prosecutors have approached at least three companies, including Johnson & Johnson, Merck & Co. and Endo International Plc., demanding information about their contracts with pharmacy benefit managers. Pharmacy…
Inefficient Prescribing Costs Billions of Healthcare Dollars
(Reuters Health)—In the U.S. between 2010 and 2012, nearly $73 billion was spent on brand name medications instead of less expensive alternatives, according to a new study. A large portion of that money was spent by patients, the researchers found. “Prescription drug prescribing during the time of this paper was not efficient and still isn’t…
Epilepsy Patients May Have Poor Bone Health, High Fracture Risk
Some patients with epilepsy have a higher risk of fracture due to falls, and some studies have suggested that anti-epileptic drugs may also contribute to the fracture risk. In a recent review, researchers examined if there is a link between epilepsy and osteoporosis, making recommendations to aid future research…
Golimumab Effective as Maintenance Treatment for Active Ulcerative Colitis
NEW YORK (Reuters Health)—Subcutaneous golimumab every four weeks provides effective long-term maintenance for patients with active ulcerative colitis (UC), according to results from the PURSUIT-SC extension study. The main PURSUIT-M study showed that golimumab treatment maintained clinical responses through Week 54. For most patients, maintenance therapy for UC is required long term. Dr. Peter R….
Tofacitinib Promising for Psoriatic Arthritis & FDA Issues Alert for Warning for Saxagliptin & Alogliptin Diabetes Treatments
A recent Phase 3 study found tofacitinib safe and effective for treating psoriatic arthritis at both 5 mg and 10 mg doses compared with placebo. And the FDA has added label warnings to saxagliptin and alogliptin for an increased risk of heart failure in individuals taking the drugs, particularly in those with heart and kidney disease…
Mucosal Healing Seen with Infliximab Biosimilar CT-P13 in Ulcerative Colitis
NEW YORK (Reuters Health)—About two-thirds of patients with ulcerative colitis (UC) had mucosal healing by the end of induction treatment with the infliximab biosimilar CT-P13, according to results of the first prospective study to evaluate this. CT-P13 is the first biosimilar monoclonal antibody of reference infliximab (Remicade) approved in Europe and several other countries where…
Regeneron Pain Drug Clears Late-Stage Trial
(Reuters)—Drugmaker Regeneron Pharmaceuticals Inc. said on Monday its experimental drug to treat moderate to severe osteoarthritis pain was successful in a late-stage study. The drug, fasinumab, was tested on 421 patients with a history of inadequate pain relief or intolerance to current painkillers. Fasinumab binds to nerve growth factor (NGF) proteins and block their activity,…
France Gets G7 to Discuss Global Regulation of Medicine Prices
PARIS (Reuters)—France will press its G7 partners this month to launch an “irreversible” process to control the prices of new medicines, part of a global drive to make life-saving drugs more affordable, three sources told Reuters. President Francois Hollande said in March he would push for the international regulation of drugs prices when he meets…
Ustekinumab Improves Spondylitis in Patients with Psoriatic Arthritis
NEW YORK (Reuters Health)—The anti-interleukin (IL)-12/IL-23 monoclonal antibody ustekinumab improves signs and symptoms of spondylitis in patients with psoriatic arthritis, according to a post-hoc analysis of data from the PSUMMIT-1 and PSUMMIT-2 trials. “This treatment did seem to have a benefit on axial symptoms,” Dr. Arthur Kavanaugh from the University of California San Diego, La…
Triple Therapy with Methotrexate Effective, Cheaper in RA
NEW YORK (Reuters Health)—The combination of methotrexate, sulphasalazine and hydroxychloroquine is similar in effect as methotrexate plus biologic therapy for patients with rheumatoid arthritis (RA), according to a new network meta-analysis. “Thus, for most patients, this low-cost combination of medications should probably be tried before moving onto biologic therapy, either as initial treatment or as…
- « Previous Page
- 1
- …
- 84
- 85
- 86
- 87
- 88
- …
- 123
- Next Page »